TY - JOUR
T1 - Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
AU - Matlung, Hanke L.
AU - Babes, Liane
AU - Zhao, Xi Wen
AU - van Houdt, Michel
AU - Treffers, Louise W.
AU - van Rees, Dieke J.
AU - Franke, Katka
AU - Schornagel, Karin
AU - Verkuijlen, Paul
AU - Janssen, Hans
AU - Halonen, Pasi
AU - Lieftink, Cor
AU - Beijersbergen, Roderick L.
AU - Leusen, Jeanette H.W.
AU - Boelens, Jaap J.
AU - Kuhnle, Ingrid
AU - van der Werff Ten Bosch, Jutte
AU - Seeger, Karl
AU - Rutella, Sergio
AU - Pagliara, Daria
AU - Matozaki, Takashi
AU - Suzuki, Eiji
AU - Menke-van der Houven van Oordt, Catharina Willemien
AU - van Bruggen, Robin
AU - Roos, Dirk
AU - van Lier, Rene A.W.
AU - Kuijpers, Taco W.
AU - Kubes, Paul
AU - van den Berg, Timo K.
N1 - Funding Information:
We are grateful to Dr. Özden Sanal (Hacettepe University, Ankara, Turkey) for providing patient material; to Ben Morris, Erik Mul, Anton Tool, and Edith van de Vijver for their help with the experiments and/or their analysis; and to Georg Kraal, Søren Moestrup, Sjaak Neefjes, and Arnoud Sonnenberg for useful discussions and for critically reading the manuscript. We also gratefully acknowledge the contribution of Joost Bakker from SciComVisuals for graphics, including the Graphical Abstract. This research was funded in part by the Dutch Cancer Society (grant no. 10300) and the Landsteiner Research Foundation (grant no. 1223).
Funding Information:
We are grateful to Dr. Özden Sanal (Hacettepe University, Ankara, Turkey) for providing patient material; to Ben Morris, Erik Mul, Anton Tool, and Edith van de Vijver for their help with the experiments and/or their analysis; and to Georg Kraal, Søren Moestrup, Sjaak Neefjes, and Arnoud Sonnenberg for useful discussions and for critically reading the manuscript. We also gratefully acknowledge the contribution of Joost Bakker from SciComVisuals for graphics, including the Graphical Abstract. This research was funded in part by the Dutch Cancer Society (grant no. 10300 ) and the Landsteiner Research Foundation (grant no. 1223 ).
Publisher Copyright:
© 2018
PY - 2018/6/26
Y1 - 2018/6/26
N2 - Destruction of cancer cells by therapeutic antibodies occurs, at least in part, through antibody-dependent cellular cytotoxicity (ADCC), and this can be mediated by various Fc-receptor-expressing immune cells, including neutrophils. However, the mechanism(s) by which neutrophils kill antibody-opsonized cancer cells has not been established. Here, we demonstrate that neutrophils can exert a mode of destruction of cancer cells, which involves antibody-mediated trogocytosis by neutrophils. Intimately associated with this is an active mechanical disruption of the cancer cell plasma membrane, leading to a lytic (i.e., necrotic) type of cancer cell death. Furthermore, this mode of destruction of antibody-opsonized cancer cells by neutrophils is potentiated by CD47-SIRPα checkpoint blockade. Collectively, these findings show that neutrophil ADCC toward cancer cells occurs by a mechanism of cytotoxicity called trogoptosis, which can be further improved by targeting CD47-SIRPα interactions.
AB - Destruction of cancer cells by therapeutic antibodies occurs, at least in part, through antibody-dependent cellular cytotoxicity (ADCC), and this can be mediated by various Fc-receptor-expressing immune cells, including neutrophils. However, the mechanism(s) by which neutrophils kill antibody-opsonized cancer cells has not been established. Here, we demonstrate that neutrophils can exert a mode of destruction of cancer cells, which involves antibody-mediated trogocytosis by neutrophils. Intimately associated with this is an active mechanical disruption of the cancer cell plasma membrane, leading to a lytic (i.e., necrotic) type of cancer cell death. Furthermore, this mode of destruction of antibody-opsonized cancer cells by neutrophils is potentiated by CD47-SIRPα checkpoint blockade. Collectively, these findings show that neutrophil ADCC toward cancer cells occurs by a mechanism of cytotoxicity called trogoptosis, which can be further improved by targeting CD47-SIRPα interactions.
KW - Animals
KW - Antibodies, Monoclonal/therapeutic use
KW - Antibody-Dependent Cell Cytotoxicity
KW - CD11b Antigen/metabolism
KW - CD18 Antigens/metabolism
KW - CD47 Antigen/metabolism
KW - Cell Line, Tumor
KW - Female
KW - Humans
KW - Male
KW - Melanoma, Experimental/metabolism
KW - Mice
KW - Mice, Inbred C57BL
KW - Neoplasms/drug therapy
KW - Neutrophils/immunology
KW - Receptors, IgG/metabolism
KW - Receptors, Immunologic/genetics
KW - Transplantation, Homologous
UR - http://www.scopus.com/inward/record.url?scp=85048859204&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2018.05.082
DO - 10.1016/j.celrep.2018.05.082
M3 - Article
C2 - 29949776
AN - SCOPUS:85048859204
SN - 2211-1247
VL - 23
SP - 3946-3959.e6
JO - Cell Reports
JF - Cell Reports
IS - 13
ER -